Clinical Trial

Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom

Name: Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom — clinical trial record (NCT07239596)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This study evaluated the safety and efficacy of SHR-8068 in combination anti-tumor drugs in the treatment of advanced renal cell carcinoma

Protocol Amendment History 2 changes

notable Enrollment reduced: 139 -> 92 participants 2026-08-12

minor Trial arms changed: 3 -> 2 2026-08-12

Trial Details

NCT Number	NCT07239596
Lead Sponsor	Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions	Advanced Renal Cell Carcinoma
Enrollment	92 participants
Start Date	2026-01-06
Primary Completion	2030-12 (estimated)
Study Completion	2030-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-11